Tango Therapeutics Stock Working Capital
| TNGX Stock | USD 3.10 0.16 5.44% |
Tango Therapeutics fundamentals help investors to digest information that contributes to Tango Therapeutics' financial success or failures. It also enables traders to predict the movement of Tango Stock. The fundamental analysis module provides a way to measure Tango Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tango Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 300.6 M | 336.8 M | |
| Change In Working Capital | -38 M | -36.1 M |
Tango | Working Capital |
Tango Therapeutics Company Working Capital Analysis
Tango Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Tango Therapeutics Working Capital | 300.6 M |
Most of Tango Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tango Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tango Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Tango Therapeutics is extremely important. It helps to project a fair market value of Tango Stock properly, considering its historical fundamentals such as Working Capital. Since Tango Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tango Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tango Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Tango Capital Lease Obligations
Capital Lease Obligations |
|
Based on the company's disclosures, Tango Therapeutics has a Working Capital of 300.6 M. This is 29.38% lower than that of the Biotechnology sector and 44.19% lower than that of the Health Care industry. The working capital for all United States stocks is 79.66% higher than that of the company.
Tango Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tango Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tango Therapeutics could also be used in its relative valuation, which is a method of valuing Tango Therapeutics by comparing valuation metrics of similar companies.Tango Therapeutics is currently under evaluation in working capital category among its peers.
Tango Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tango Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tango Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Tango Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.84) % | ||||
| Operating Margin | (2.83) % | ||||
| Current Valuation | 77.34 M | ||||
| Shares Outstanding | 107.42 M | ||||
| Shares Owned By Insiders | 12.84 % | ||||
| Shares Owned By Institutions | 87.16 % | ||||
| Number Of Shares Shorted | 7.22 M | ||||
| Price To Book | 1.45 X | ||||
| Price To Sales | 7.68 X | ||||
| Revenue | 36.53 M | ||||
| Gross Profit | (81.05 M) | ||||
| EBITDA | (111.76 M) | ||||
| Net Income | (101.74 M) | ||||
| Cash And Equivalents | 416.36 M | ||||
| Cash Per Share | 4.73 X | ||||
| Total Debt | 38.92 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.76 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (117.98 M) | ||||
| Short Ratio | 2.31 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 140 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 333 M | ||||
| Total Asset | 402.57 M | ||||
| Retained Earnings | (371.26 M) | ||||
| Working Capital | 300.6 M | ||||
| Net Asset | 402.57 M |
About Tango Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tango Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tango Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tango Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.